AI in Drug DiscoveryWith an explosion of interest in artificial intelligence applications for drug discovery and biomedical research, the official release of Claude Science by Anthropic marks a significant development for the life sciences industry. This new application, tailored for the unique needs of researchers and pharmaceutical professionals, optimizes emerging AI technology to fundamentally reshape how complex scientific problems are tackled.
Dr. Priya Nandakumar·Jun 30, 2026
Regulatory & PolicyThe FDA's move to include longevity and wellness experts on a committee that will soon advise on relaxing peptide compound restrictions is attracting both interest and concern across the biomedical landscape. This development highlights the increasingly complex intersection of wellness, regulatory oversight, and public trust.
Dr. Priya Nandakumar·Jun 30, 2026 
Regulatory & PolicyWith nearly half of U.S. states launching legal action against federal Medicaid work requirements, the clash underscores the persistent divides in American health policy. The lawsuits reflect wide-ranging concerns about access to care, administrative burden, and the intersection between social welfare and labor policy.
Dr. Priya Nandakumar·Jun 30, 2026 
Regulatory & PolicyAs medetomidine-laced opioids circulate among incarcerated populations, correctional facilities are being forced into a new role as first responders for a uniquely severe withdrawal syndrome. The complexity of the issue—from the pharmacology of medetomidine to resource gaps in prisons—poses new challenges for public health, addiction medicine, and criminal justice policy. We analyze the evolving situation, the gaps in care, and where systemic responses may fall short or present hope.
Dr. Priya Nandakumar·Jun 27, 2026 
Biopharmaceutical IndustryThe recent wave of layoffs at ADC Therapeutics comes after the company reported 27 patient deaths among recipients of its blood cancer therapy, Zynlonta. This development underscores the major risks biotech companies shoulder as they balance clinical innovation and patient safety, while facing financial and regulatory pressures.
Dr. Priya Nandakumar·Jun 24, 2026 
Regulatory & PolicyThe tension between pharmaceutical giant Eli Lilly and U.S. hospitals has reached a new peak as the company enforces stricter claims data requirements for 340B drug discounts. Health systems, already under pressure, argue the move could undermine the very fabric of a program designed to serve some of the nation's most vulnerable patients.
Dr. Priya Nandakumar·Jun 23, 2026 
Biotech InnovationBiotech start-up Cambrian’s latest development—a drug that reportedly mimics the effects of physical exercise—raises major questions about the future of aging, disease prevention, and the intersection of biotechnology with lifestyle interventions. Early reports prompt both excitement and skepticism within the medical and scientific communities.
Dr. Priya Nandakumar·Jun 21, 2026 
Regulatory & PolicyAs UniQure prepares a third-quarter submission for its Huntington’s disease gene therapy, many in the biopharmaceutical industry are watching the FDA’s approach under acting commissioner Kyle Diamantas for signs of lasting change. This feature examines the evolving regulatory landscape and explores whether recent displays of flexibility represent a new permanent direction, or are simply the calm before the next wave of policy shifts.
Dr. Priya Nandakumar·Jun 20, 2026 
Regulatory & PolicyA dramatic surge in Ebola cases in Congo and Uganda underscores the urgency of coordinated global health responses and offers a sobering look at ongoing gaps in outbreak detection and containment. With the death toll crossing 200 and public health infrastructure under strain, regional and international collaboration will be pivotal in containing the epidemic and preventing further spread across borders.
Dr. Priya Nandakumar·Jun 19, 2026 
Regulatory & PolicyMedicare Advantage star ratings have always played a pivotal role in determining which plans receive lucrative bonus payments from CMS. This recalculation, arriving amid ongoing industry lawsuits and heated scrutiny, is causing fresh uncertainty for plans and providers.
Dr. Priya Nandakumar·Jun 19, 2026 
Regulatory & PolicyIn a significant regulatory development, the Department of Justice secured a swift settlement in its antitrust case against OhioHealth. This outcome is sending ripples across the healthcare landscape, urging other hospitals and large health systems to reassess their contracting strategies and ensure compliance with antitrust laws.
Dr. Priya Nandakumar·Jun 18, 2026 
AI in Drug DiscoveryThe partnership between Merck and Protillion represents a substantial investment in artificial intelligence for drug discovery, specifically targeting the development of biologic therapies for unknown indications. As AI continues to revolutionize the way new medicines are designed and optimized, this high-value collaboration may mark a significant turning point in how big pharma approaches early-stage research and portfolio development.
Dr. Priya Nandakumar·Jun 17, 2026 